Arvinas, Inc.

Arvinas, Inc. is a clinical-stage biotechnology company headquartered in New Haven, Connecticut, dedicated to improving the lives of patients with serious diseases. The company's mission is to pioneer therapies using its revolutionary PROTAC® protein degradation platform.

Arvinas' core business revolves around its proprietary PROTAC® (PROteolysis TArgeting Chimera) technology, which harnesses the body's natural protein disposal system to selectively degrade and remove disease-causing proteins. This innovative approach aims to address a range of diseases, particularly in oncology and neurodegenerative disorders, including targets previously considered "undruggable." The company's pipeline features several investigational drugs, such as ARV-102 for Parkinson's disease, ARV-806 for various solid tumors, ARV-393 for non-Hodgkin lymphoma, and ARV-027 for spinal-bulbar muscular atrophy.

A significant recent development for Arvinas is the FDA approval of VEPPANU (vepdegestrant) on May 1, 2026, for the treatment of ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer. This marks a transformative milestone as VEPPANU is the first FDA-approved PROTAC drug, demonstrating the clinical viability of the company's platform. Arvinas, in collaboration with Pfizer, plans to select a third-party commercial partner for VEPPANU. Leadership transitioned in February 2026, with Randy Teel, Ph.D., appointed as President and Chief Executive Officer.